Difference between revisions of "Team:ETH Zurich"

Line 134: Line 134:
 
       <br>
 
       <br>
 
       <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a>
 
       <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a>
−
</div>
+
    </div>
  
 +
  <div id="third">
 +
      <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png width="400px" align="center">
 +
  </div>
  
  

Revision as of 14:48, 7 October 2017



Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.

Learn more
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.

We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.

Project description